Ascletis Pharma Completes Dosing in U.S. Clinical Trial for Obesity Treatment Combining ASC47 and Semaglutide

Reuters

2025/07/15

Ascletis Pharma Completes Dosing in U.S. Clinical Trial for Obesity Treatment Combining ASC47 and Semaglutide

Ascletis Pharma Inc. has announced the completion of dosing for all participants in its U.S. clinical study that combines the adipose-targeted, once-monthly injectable small molecule THR-beta agonist, ASC47, with semaglutide for the treatment of obesity. The study, identified as ASC47-103 (NCT06972992), involves a randomized, double-blind, placebo-controlled design and includes 28 participants without type 2 diabetes. The participants are divided into three cohorts, receiving single ascending doses of ASC47 (10 mg, 30 mg, and 60 mg) or a placebo, along with four doses of semaglutide (0.5 mg, once weekly). The enrollment process was completed in less than two months. Ascletis plans to present topline data from the trial in the fourth quarter of 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief on July 15, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2551395411"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2551395411\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2551395411?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-15 06:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551395411","market":"nz","top_or_hot":-1,"title":"Ascletis Pharma Completes Dosing in U.S. Clinical Trial for Obesity Treatment Combining ASC47 and Semaglutide","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ascletis Pharma Completes Dosing in U.S. Clinical Trial for Obesity Treatment Combining ASC47 and Semaglutide\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ASCLF\">Ascletis Pharma Inc.</a> has announced the completion of dosing for all participants in its U.S. clinical study that combines the adipose-targeted, once-monthly injectable small molecule THR-beta agonist, ASC47, with semaglutide for the treatment of obesity. The study, identified as ASC47-103 (NCT06972992), involves a randomized, double-blind, placebo-controlled design and includes 28 participants without type 2 diabetes. The participants are divided into three cohorts, receiving single ascending doses of ASC47 (10 mg, 30 mg, and 60 mg) or a placebo, along with four doses of semaglutide (0.5 mg, once weekly). The enrollment process was completed in less than two months. Ascletis plans to present topline data from the trial in the fourth quarter of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief on July 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascletis Pharma Completes Dosing in U.S. Clinical Trial for Obesity Treatment Combining ASC47 and Semaglutide</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscletis Pharma Completes Dosing in U.S. Clinical Trial for Obesity Treatment Combining ASC47 and Semaglutide\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-15 06:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ascletis Pharma Completes Dosing in U.S. Clinical Trial for Obesity Treatment Combining ASC47 and Semaglutide\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ASCLF\">Ascletis Pharma Inc.</a> has announced the completion of dosing for all participants in its U.S. clinical study that combines the adipose-targeted, once-monthly injectable small molecule THR-beta agonist, ASC47, with semaglutide for the treatment of obesity. The study, identified as ASC47-103 (NCT06972992), involves a randomized, double-blind, placebo-controlled design and includes 28 participants without type 2 diabetes. The participants are divided into three cohorts, receiving single ascending doses of ASC47 (10 mg, 30 mg, and 60 mg) or a placebo, along with four doses of semaglutide (0.5 mg, once weekly). The enrollment process was completed in less than two months. Ascletis plans to present topline data from the trial in the fourth quarter of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief on July 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nNDL6Kd4cT:1","article_id":"2551395411","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2551395411","pubTimestamp":1752533493,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ascletis Pharma Inc. has announced the completion of dosing for all participants in its U.S. clinical study that combines the adipose-targeted, once-monthly injectable small molecule THR-beta agonist, ASC47, with semaglutide for the treatment of obesity. The study, identified as ASC47-103 , involves a randomized, double-blind, placebo-controlled design and includes 28 participants without type 2 diabetes. The participants are divided into three cohorts, receiving single ascending doses of ASC47  or a placebo, along with four doses of semaglutide . The enrollment process was completed in less than two months. Ascletis plans to present topline data from the trial in the fourth quarter of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advic","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股","01672":"歌礼制药-B"},"translate_title":"歌礼制药联合ASC47和索马鲁肽治疗肥胖美国临床试验完成给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":0.9},"content_text":"Ascletis Pharma Completes Dosing in U.S. Clinical Trial for Obesity Treatment Combining ASC47 and Semaglutide\n    \n\nAscletis Pharma Inc. has announced the completion of dosing for all participants in its U.S. clinical study that combines the adipose-targeted, once-monthly injectable small molecule THR-beta agonist, ASC47, with semaglutide for the treatment of obesity. The study, identified as ASC47-103 (NCT06972992), involves a randomized, double-blind, placebo-controlled design and includes 28 participants without type 2 diabetes. The participants are divided into three cohorts, receiving single ascending doses of ASC47 (10 mg, 30 mg, and 60 mg) or a placebo, along with four doses of semaglutide (0.5 mg, once weekly). The enrollment process was completed in less than two months. Ascletis plans to present topline data from the trial in the fourth quarter of 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief on July 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}